Fintel reports that on October 10, 2025, Benchmark initiated coverage of Abbott Laboratories (NYSE:ABT) with a Buy recommendation.
Analyst Price Forecast Suggests 9.04% Upside
As of September 29, 2025, the average one-year price target for Abbott Laboratories is $144.58/share. The forecasts range from a low of $123.37 to a high of $166.95. The average price target represents an increase of 9.04% from its latest reported closing price of $132.59 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Abbott Laboratories is 44,390MM, an increase of 2.97%. The projected annual non-GAAP EPS is 4.71.
What is the Fund Sentiment?
There are 4,446 funds or institutions reporting positions in Abbott Laboratories. This is an increase of 87 owner(s) or 2.00% in the last quarter. Average portfolio weight of all funds dedicated to ABT is 0.57%, an increase of 2.65%. Total shares owned by institutions increased in the last three months by 0.84% to 1,644,853K shares. 
The put/call ratio of ABT is 0.72, indicating a bullish outlook.
What are Other Shareholders Doing?
Capital International Investors holds 60,137K shares representing 3.46% ownership of the company. In its prior filing, the firm reported owning 66,824K shares , representing a decrease of 11.12%. The firm decreased its portfolio allocation in ABT by 19.18% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 55,945K shares representing 3.21% ownership of the company. In its prior filing, the firm reported owning 54,801K shares , representing an increase of 2.04%. The firm decreased its portfolio allocation in ABT by 6.61% over the last quarter.
VFINX - Vanguard 500 Index Fund Investor Shares holds 49,386K shares representing 2.84% ownership of the company. In its prior filing, the firm reported owning 48,194K shares , representing an increase of 2.42%. The firm decreased its portfolio allocation in ABT by 6.65% over the last quarter.
Capital Research Global Investors holds 41,766K shares representing 2.40% ownership of the company. In its prior filing, the firm reported owning 50,734K shares , representing a decrease of 21.47%. The firm decreased its portfolio allocation in ABT by 22.28% over the last quarter.
Jpmorgan Chase holds 39,304K shares representing 2.26% ownership of the company. In its prior filing, the firm reported owning 39,924K shares , representing a decrease of 1.58%. The firm decreased its portfolio allocation in ABT by 9.60% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
